|
Objective: To observe the diastolic heart failure (DHF) changes in the blood of patients with hs-CRP levels and Qili cardiac capsules intervention role, initially explore the the Qili strong heart capsule treatment of DHF clinical efficacy and mechanism of action. Methods: 70 patients with chronic diastolic heart failure patients were randomly divided into two groups, 35 cases in each group, the two groups were given diuretics, vasodilators, angiotensin-converting enzyme inhibitors (ACEI), β2 receptor blocking stagnation agents and calcium antagonists, such as conventional western medicine treatment group add services on this basis Qili cardiac capsules, control group taking the appearance, taste and Qili cardiac capsule similar to the placebo, the course of treatment was 12 months. To routine blood, urine, stool routine, liver and kidney function and other laboratory tests as a safety indicator, to determine of Qili cardiac capsule whether the toxic side effects. Observed two clinical efficacy and treatment before and after TCM syndrome score, functional class assessment, 6-minute walk distance, echocardiography the Figure, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-CRP) changes observed two sets of relapse rate, mortality, and adverse reactions. Of cardiac function, NT-proBNP and hs-CRP correlation. Results: the treatment of the Qili cardiac capsule group total effective rate was 85.71%, better than the control group (71.43%), P lt; 0.05; treatment in the two groups can improve heart function, improve the quality of life of patients, an increase of 6 minutes walking distance, improve echocardiography diastolic function, reduce the level of NT-proBNP (P lt; 0.05), but the effect of the treatment group compared with the control group significantly (P lt; 0.05), the treatment group can reduce the plasma levels of hs-CRP levels (P lt ; 0.05), correlation analysis found blood hs-CRP levels and heart function classification, NT-proBNP was positively correlated with a correlation coefficient r = 0.71,0.48 (P lt; 0.05). During treatment, control group patients rash treatment group 1 patients had gastrointestinal symptoms, symptomatic improvement after treatment. The remaining patients with no adverse reactions. Conclusion: diastolic heart failure in patients with blood hs-CRP levels in patients with heart function and NT-proBNP was positively related to the Qili cardiac capsules can reduce the level of the same time improve the DHF patients with cardiac diastolic function and clinical symptoms, reduce DHF patients relapse rate and mortality and improve the patient's 6-minute walk distance and quality of life. Qili cardiac capsule treatment of diastolic heart failure mechanism may improve patients' cardiovascular inflammatory response.
|